Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study-Reference-Cited by-同舟云学术

Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study

Published:2008-03 Issue:3 Volume:22 Page:345-352
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venerol

Author:

Tsai TF,Liu MT,Liao YH,Licu D

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1468-3083.2007.02430.x/fullpdf

Reference31 articles.

1. Psoriasis: epidemiology, clinical features, and quality of life

2. Getting under the skin: the immunogenetics of psoriasis

3. T-Cell Modulation for the Treatment of Chronic Plaque Psoriasis with Efalizumab (Raptiva™): Mechanisms of Action

4. A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis

5. Clinical Efficacy of Efalizumab in Patients With Chronic Plaque Psoriasis: Results From Three Randomized Placebo-Controlled Phase III Trials: Part I

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjects;British Journal of Clinical Pharmacology;2020-12-09

2. Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis;Expert Review of Clinical Pharmacology;2020-03-03

3. Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience;Dermatology and Therapy;2019-07-03

4. How Long Does the Benefit of Biologics Last? An Update on Time to Relapse and Potential for Rebound of Biologic Agents for Psoriasis;Journal of Psoriasis and Psoriatic Arthritis;2018-04

5. Biological therapies (immunomodulatory drugs), worsening of psoriasis and rebound effect: new evidence of similitude;Homeopathy;2016-11